FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple kinase inhibitors of EGFR family proteins such as afatinib have been newly developed to overcome such drug resistance. We es...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Azuma, Koichi, Kawahara, Akihiko, Sonoda, Kahori, Nakashima, Kazutaka, Tashiro, Kousuke, Watari, Kosuke, Izumi, Hiroto, Kage, Masayoshi, Kuwano, Michihiko, Ono, Mayumi, Hoshino, Tomoaki
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2014
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171601/
https://ncbi.nlm.nih.gov/pubmed/25115383
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы